Baxter’s VIVIA hemodialysis system lands CE Marking in the European Union with indication for more frequent, extended duration, short daily or nocturnal home high-dose therapy.
Illinois medical device maker Baxter‘s (NYSE:BAX) won European regulatory approval for its VIVIA hemodialysis system, designed for use in multiple settings and therapy regimens.
The VIVIA system, designed to be operated primarily by a patient, is indicated for use in “more frequent, extended duration, short daily or nocturnal home [high-dose] therapy,” Baxter said. VIVIA features touch-screen technology, a graphic interface and animations that guide patients through setup, treatment and cleanup.
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)
![A photo of the Northwestern University pacemaker surrounded by grains of rice for scale [Photo courtesy of Northwestern]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Worlds-smallest-pacemaker-Northwestern-wearable-268x170.jpg)